US President Trump says vaccinations for Hepatitis B, Covid-19, and Influenza, among others, are no longer recommended for all children

• Child vaccines will still be covered by insurance.

Changes of this kind to recommended paediatric schedules sit with the advisory and regulatory apparatus rather than with the President, so the operative question is whether this statement translates into formal guidance, and on what timeline. Past episodes where recommendation status was narrowed have tended to matter through two distinct channels: uptake, which follows physician and school-entry practice more than the recommendation itself, and liability and procurement frameworks that attach to schedule inclusion. The insurance-coverage carve-out in the detail is the key mitigant; where coverage survives, the volume effect on routine shots has historically been muted, whereas seasonal products sold into discretionary demand, notably Covid boosters, are more exposed to any signal that de-prioritises them. The named vaccine developers trade on exactly that seasonal demand assumption, so the read-across falls unevenly across the peer set rather than uniformly. Worth watching is whether the agencies act on the statement, whether any formal schedule revision follows, and how states and insurers respond, since those are the steps that have determined real-world uptake in comparable disputes.